$14.97
0.48% today
NYSE, Feb 28, 05:22 pm CET
ISIN
US68622V1061
Symbol
OGN

Organon & Co. Stock price

$15.04
-1.22 7.50% 1M
-7.37 32.89% 6M
+0.12 0.80% YTD
-3.00 16.63% 1Y
-22.29 59.71% 3Y
-18.21 54.77% 5Y
-18.21 54.77% 10Y
NYSE, Closing price Thu, Feb 27 2025
-0.44 2.84%
ISIN
US68622V1061
Symbol
OGN
Sector
Industry

Key metrics

Market capitalization $3.87b
Enterprise Value $12.10b
P/E (TTM) P/E ratio 4.51
EV/Sales (TTM) EV/Sales 1.89
P/S ratio (TTM) P/S ratio 0.60
P/B ratio (TTM) P/B ratio 7.86
Dividend yield 7.45%
Last dividend (FY24) $1.12
Revenue growth (TTM) Revenue growth 2.24%
Revenue (TTM) Revenue $6.40b
EBIT (operating result TTM) EBIT $1.49b
Cash position $763.00m
EPS (TTM) EPS $3.33
P/E forward 3.81
P/S forward 0.59
EV/Sales forward 1.84
Short interest 8.59%
Show more

Is Organon & Co. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Organon & Co. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Organon & Co. forecast:

4x Buy
40%
4x Hold
40%
2x Sell
20%

Analyst Opinions

10 Analysts have issued a Organon & Co. forecast:

Buy
40%
Hold
40%
Sell
20%

Financial data from Organon & Co.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6,403 6,403
2% 2%
100%
- Direct Costs 2,688 2,688
7% 7%
42%
3,715 3,715
1% 1%
58%
- Selling and Administrative Expenses 1,484 1,484
10% 10%
23%
- Research and Development Expense 469 469
11% 11%
7%
1,762 1,762
13% 13%
28%
- Depreciation and Amortization 276 276
17% 17%
4%
EBIT (Operating Income) EBIT 1,486 1,486
12% 12%
23%
Net Profit 864 864
16% 16%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Organon & Co. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Organon & Co. Stock News

Positive
MarketBeat
12 days ago
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income.
Neutral
Seeking Alpha
15 days ago
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - ...
Neutral
Business Wire
15 days ago
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024.
More Organon & Co. News

Company Profile

Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.

Head office United States
CEO Kevin Ali
Founded 2020
Website www.organon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today